# US 2006/0052350 A1 · Crystalline forms of 1,24(S)-dihydroxy vitamin D2

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0052350 A1
- Document ID: US20060052350A1
- Status: Published application
- Kind: A1
- Application number: 11/173,514
- Filed: 2005-07-01
- Published: 2006-03-09
- Earliest claimed: 2004-07-01
- Inventors: Alexei Ploutno; Anchel Schwartz; Koby Wolfman; Judith Aronhime
- Web page: https://patentgrep.com/patent/US20060052350A1

## CPC

- C07C 401/00: Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are novel crystalline forms of 1,24-(S)-dihydroxy vitamin D2, including hydrates and solvates, and methods for making them. Also provided are pharmaceutical and nutraceutical compositions containing the novel crystalline forms.

## Claims

### Claim 1

1,24(S)-dihydroxy vitamin D2 hydrate.

### Claim 2 (depends on 1)

The 1,24(S)-dihydroxy vitamin D2 hydrate of claim 1, containing between about 1% to about 4% water.

### Claim 3 (depends on 1)

The 1,24(S)-dihydroxy vitamin D2 hydrate of claim 1, wherein the hydrate is selected from the group consisting of: a monohydrate, a hemihydrate and a sesquihydrate.

### Claim 4

1,24(S)-dihydroxy vitamin D2 solvate.

### Claim 5 (depends on 4)

The 1,24(S)-dihydroxy vitamin D2 solvate of claim 4, wherein the solvate is an acetonate.

### Claim 6 (depends on 5)

The 1,24(S)-dihydroxy vitamin D2 solvate of claim 5, wherein the solvate is a hemi-acetonate.

### Claim 7

A crystalline form of 1,24(S)-dihydroxy vitamin D2 characterized by X-ray reflections at about 14.2, 16.2, 16.6, 18.4, and 22.1°±0.2° 2θ.

### Claim 8 (depends on 7)

The crystalline form of 1,24(S)-dihydroxy vitamin D2 of claim 7, further characterized by X-ray reflections at about 7.2, 12.0, 14.8, 23.0, 23.8, 24.7, and 27.9°±0.2° 2θ.

### Claim 9 (depends on 8)

The crystalline form of 1,24(S)-dihydroxy vitamin D2 of claim 8, having a powder X-ray diffraction diagram substantially as shown in FIG. 1.

### Claim 10 (depends on 7)

The crystalline form of 1,24(S)-dihydroxy vitamin D2 of claim 7, wherein the crystalline form is a hemi-acetonate.

### Claim 11 (depends on 7)

A method of making the crystalline form of 1,24(S)-dihydroxy vitamin D2 of claim 7 comprising the steps of: providing a solution of 1,24(S) dihydroxy vitamin D2 in acetone, cooling the solution to a temperature of about 0° C. to about −20° C., maintaining the resulting cooled mixture for at least about 15 hours to obtain a precipitate, and recovering the crystalline form.

### Claim 12 (depends on 11)

The method of claim 11, wherein the solution is cooled to a temperature of about −18° C.

### Claim 13 (depends on 11)

The method of claim 11, wherein the solution is initially cooled to a temperature of about 0° C. and maintained for a period of about 1 hour, followed by further cooling to a temperature of about −18° C.

### Claim 14 (depends on 11)

The method of claim 11, wherein prior to cooling, the solution is concentrated to about 70% to about 85% of its initial volume.

### Claim 15

A crystalline form of 1,24(S)-dihydroxy vitamin D2 characterized by X-ray reflections at about 13.6, 15.3, 16.2, 17.1, and 17.6°±0.2° 2θ.

### Claim 16 (depends on 15)

The crystalline form 1,24(S)-dihydroxy vitamin D2 of claim 15, further characterized by X-ray reflections at about 13.6, 15.3, 16.2, 17.1, and 17.6°±0.2° 2θ.

### Claim 17 (depends on 16)

The crystalline form of 1,24(S) dihydroxy vitamin D2 of claim 16 having a powder X-ray diffraction diagram substantially as shown in FIG. 2.

### Claim 18 (depends on 15)

The 1,24(S)-dihydroxy vitamin D2 solvate of claim 15, wherein the crystalline form is a monohydrate.

### Claim 19 (depends on 15)

A method of making the crystalline form of 1,24(S)-dihydroxy vitamin D2 of claim 15 comprising the steps of: providing a solution of 1,24(S)-dihydroxy vitamin D2 in a mixture of water and methyl formate, cooling the provided solution to a temperature of about 0° C. to about −20° C., maintaining the reaction mixture for a period of about 16 to about 19 hours to obtain a precipitate, and recovering the crystalline form.

### Claim 20 (depends on 19)

The method of claim 19, wherein the solution is initially cooled to a temperature of about 0° C. and maintained for a period of about 1 hour, followed by further cooling to a temperature of about −18° C.

### Claim 21 (depends on 19)

The method of claim 19, wherein the water and methyl formate are about 1:50 on a volume basis.

### Claim 22 (depends on 15)

A method of making the crystalline form of 1,24(S)-dihydroxy vitamin D2 of claim 15 comprising the steps of: providing a solution of 1,24(S)-dihydroxy vitamin D2 in a mixture of acetone and water, cooling the provided solution to a temperature of about 0° C. for a period of about 1.5 hours to obtain a precipitate, and recovering the crystalline form.

### Claim 23 (depends on 22)

The method of claim 22, wherein the water and acetone are about 1:3 on a volume basis.

### Claim 24

A crystalline form of 1,24(S)-dihydroxy vitamin D2 characterized by X-ray reflections at about 14.7, 15.6, 16.2, and 17.1°±0.2° 2θ.

### Claim 25 (depends on 24)

The crystalline form of 1,24(S)-dihydroxy vitamin D2 of claim 24, further characterized by X-ray reflections at about 6.2, 13.4, 18.4, and 18.8°±0.2° 2θ.

### Claim 26 (depends on 25)

The crystalline form of 1,24(S)-dihydroxy vitamin D2 of claim 25, having a powder x-ray diffraction diagram substantially as shown in FIG. 3.

### Claim 27 (depends on 24)

The crystalline form of 1,24(S)-dihydroxy vitamin D2 of claim 24, wherein the crystalline form is a hemihydrate.

### Claim 28 (depends on 24)

A method of making the crystalline form of 1,24(S)-dihydroxy vitamin D2 of claim 24 comprising the steps of: providing a solution of 1,24(S) dihydroxy vitamin D2 in ethyl acetate, cooling the solution to a temperature of about −10° C. to about −20° C., maintaining the cooled solution for about 5 to about 20 hours to obtain a precipitate, and recovering the crystalline form.

### Claim 29 (depends on 28)

The method of claim 28, wherein the solution is cooled to a temperature of about −18° C.

### Claim 30 (depends on 28)

The method of claim 28, wherein the cooled solution is maintained for about 18 hours.

### Claim 31 (depends on 28)

The method of claim 28, wherein prior to cooling, the solution is concentrated to about 60% to about 80% of its initial volume.

### Claim 32

A crystalline form of 1,24(S)-dihydroxy vitamin D2, characterized by X-ray reflections at about 13.4, 14.5, 15.0, and 16.8°±0.2° 2θ.

### Claim 33 (depends on 32)

The crystalline form of 1,24(S)-dihydroxy vitamin D2 of claim 32, further characterized by X-ray reflections at about 6.0, 15.6, 16.4, 17.8, 20.5, 21.8, 23.1, 24.6, and 24.9°±0.2° 2θ.

### Claim 34 (depends on 33)

The crystalline form of 1,24(S)-dihydroxy vitamin D2 of claim 33 having a powder X-ray diffraction diagram substantially as shown in FIG. 4.

### Claim 35 (depends on 32)

The crystalline form of 1,24(S)-dihydroxy vitamin D2 of claim 32, wherein the crystalline form is a sesquihydrate.

### Claim 36 (depends on 32)

A method of making the crystalline form of 1,24(S)-dihydroxy vitamin D2 of claim 32 comprising the steps of: providing a solution of 1,24(S)-dihydroxy vitamin D2 in a solvent selected from methyl formate or ethyl acetate, cooling the provided solution to a temperature of about 0° C. for about 1 hour, further cooling to a temperature of about −10° to about −20° C., maintaining the reaction mixture for about 16 to about 19 hours to obtain a precipitate, and recovering the crystalline form.

### Claim 37 (depends on 28)

The method of claim 28, wherein prior to cooling, the solution is concentrated to about 60% to about 80% of its initial volume.

### Claim 38 (depends on 1, 4, 7, 15, 24, 32)

A pharmaceutical or nutraceutical composition prepared by combining at least one pharmaceutically acceptable excipient with at least one of the crystalline forms of 1,24(S)-dihydroxy vitamin D2 of any one of claims 1, 4, 7, 15, 24 and 32.
